Aberrant promoter methylation in overexpression of CITED1 in papillary thyroid cancer

Thyroid

Volumn 21, Issue 5, 2011, Pages 511-517

  Sassa, Miho ^a,b   Hayashi, Yoshitaka ^a   Watanabe, Reiko ^a,b   Kikumori, Toyone ^b   Imai, Tsuneo ^b   Kurebayashi, Junichi ^c   Kiuchi, Tetsuya ^b   Murata, Yoshiharu ^a  

^a NAGOYA UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; B RAF KINASE; CBP P300 INTERACTING TRANSACTIVATORS WITH GLUTAMIC ACID AND ASPARTIC ACID RICH C TERMINAL DOMAIN 1 PROTEIN; CPG 10101; MESSENGER RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; THYROID PAPILLARY CARCINOMA;

ADULT; AGED; AZACITIDINE; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; THYROID NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 79957442018     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2010.0295     Document Type: Article

References (39)

1. Leenhardt L, Grosclaude P, Cherie-Challine L 2004 Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 14:1056-1060. (Pubitemid 40076130)
2. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167.
3. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in theU.S., 1985-1995. Cancer 83:2638-2648. (Pubitemid 29019586)
4. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS 1993 Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050-1057; discussion 1057-1058.
5. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428. (Pubitemid 24345593)
6. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T, Maxon HR, 3rd 1998 Prospective multicenter study of thyrois]carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 83:1012-1021. (Pubitemid 28401936)
7. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A 2009 BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56:89-97.
8. Marais R, Marshall CJ 1996 Control of the ERK MAP kinase cascade by Ras and Raf. Cancer Surv 27:101-125. (Pubitemid 26363825)
9. Mercer KE, Pritchard CA 2003 Raf proteins and cancer: BRaf is identified as a mutational target. Biochim Biophys Acta 1653:25-40. (Pubitemid 36627818)
10. Robinson MJ, Cobb MH 1997 Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9:180-186. (Pubitemid 27135985)
11. Schaeffer HJ, Weber MJ 1999 Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 19:2435-2444. (Pubitemid 29144487)
12. Kolch W 2000 Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351 Pt 2:289-305.
13. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA 2002 Mutations of the BRAF gene in human cancer. Nature 417:949-954. (Pubitemid 34716871)
14. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S 2003 Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393-4397. (Pubitemid 37153748)
15. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457. (Pubitemid 36373628)
16. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762. (Pubitemid 350294294)
17. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D 2003 BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625-627. (Pubitemid 36553510)
18. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA 2003 High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63:4561-4567. (Pubitemid 36951030)
19. Kumagai A, Namba H, Akanov Z, Saenko VA, Meirmanov S, Ohtsuru A, Yano H, Maeda S, Anami M, Hayashi T, Ito M, Sagandikova S, Eleubaeva Z, Mussinov D, Espenbetova M, Yamashita S 2007 Clinical implications of pre-operative rapid BRAF analysis for papillary thyroid cancer. Endocr J 54:399-405. (Pubitemid 47105427)
20. Xing M 2005 BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245-262. (Pubitemid 40896444)
21. Powell N, Jeremiah S, Morishita M, Dudley E, Bethel J, Bogdanova T, Tronko M, Thomas G 2005 Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure. J Pathol 205:558-564. (Pubitemid 40514828)
22. Xing M, Vasko V, Tallini G, Larin A, Wu G, Udelsman R, Ringel MD, Ladenson PW, Sidransky D 2004 BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab 89:1365-1368. (Pubitemid 38368438)
23. Watanabe R, Hayashi Y, Sassa M, Kikumori T, Imai T, Kiuchi T, Murata Y 2009 Possible involvement of BRAFV600E in altered gene expression in papillary thyroid cancer. Endocr J 56:407-414.
24. Nikiforova MN, Nikiforov YE 2009 Molecular diagnostics and predictors in thyroid cancer. Thyroid 19:1351-1361.
25. Tang KT, Lee CH 2010 BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J Chin Med Assoc 73:113-128.
26. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, LiVolsi V, Frankel W, Kloos RT, Eng C, Pellegata NS, de la Chapelle A 2001 Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA 98:15044-15049. (Pubitemid 34013966)
27. Prasad ML, Pellegata NS, Kloos RT, Barbacioru C, Huang Y, de la Chapelle A 2004 CITED1 protein expression suggests papillary thyroid carcinoma in high throughput tissue microarray-based study. Thyroid 14:169-175. (Pubitemid 38452188)
28. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR 2008 Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93: 4331-4341. (Pubitemid 352789529)
29. Feinberg AP 2005A genetic approach to cancer epigenetics. Cold Spring Harb Symp Quant Biol 70:335-341. (Pubitemid 44124888)
30. Jones PA, Baylin SB 2007 The epigenomics of cancer. Cell 128:683-692. (Pubitemid 46273572)
31. Miyamoto K, Asada K, Fukutomi T, Okochi E, Yagi Y, Hasegawa T, Asahara T, Sugimura T, Ushijima T 2003 Methylation-associated silencing of heparan sulfate Dglucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers. Oncogene 22: 274-280. (Pubitemid 36174184)
32. Scarpino S, Di Napoli A, Rapazzotti-Onelli M, Pilozzi E, Ruco L 2004 Papillary carcinoma of the thyroid: methylation is not involved in the regulation of MET expression. Br J Cancer 91:703-706. (Pubitemid 39141628)
33. Kitamoto S, Yamada N, Yokoyama S, Houjou I, Higashi M, Yonezawa S 2010 Promoter hypomethylation contributes to the expression of MUC3A in cancer cells. Biochem Biophys Res Commun 397:333-339.
34. Maddodi N, Bhat KM, Devi S, Zhang SC, Setaluri V 2010 Oncogenic BRAFV600E induces expression of neuronal differentiation marker MAP2 in melanoma cells by promoter demethylation and down-regulation of transcription repressor HES1. J Biol Chem 285:242-254.
35. Ishizaka Y, Itoh F, Tahira T, Ikeda I, Ogura T, Sugimura T, Nagao M 1989 Presence of aberrant transcripts of ret protooncogene in a human papillary thyroid carcinoma cell line. Jpn J Cancer Res 80:1149-1152. (Pubitemid 20050979)
36. Challeton C, Branea F, Schlumberger M, Gaillard N, de Vathaire F, Badie C, Antonini P, Parmentier C 1997 Characterization and radiosensitivity at high or low dose rate of four cell lines derived from human thyroid tumors. Int J Radiat Oncol Biol Phys 37:163-169. (Pubitemid 27090149)
37. Kurebayashi J, Tanaka K, Otsuki T, Moriya T, Kunisue H, Uno M, Sonoo H 2000 All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metab 85:2889-2896. (Pubitemid 32269169)
38. Leakey TI, Zielinski J, Siegfried RN, Siegel ER, Fan CY, Cooney CA 2008A simple algorithm for quantifying DNA methylation levels on multiple independent CpG sites in bisulfite genomic sequencing electropherograms. Nucleic Acids Res 36:e64.
39. Xing M, Usadel H, Cohen Y, Tokumaru Y, Guo Z, Westra WB, Tong BC, Tallini G, Udelsman R, Califano JA, Ladenson PW, Sidransky D 2003 Methylation of the thyroidstimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res 63:2316-2321. (Pubitemid 36538643)